You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ID: GL-END 3-25 nov 2023
Type of Content: Guidelines & Advice, Advice Report
Document Status: Current
Authors:
K. Zukotynski, C. Arinze, G. Kulkarni, S. Hotte, A. Loblaw, Genitourinary Disease Site Group

Objective

The objectives of this guideline are to provide guidance for the most contemporary management for men with metastatic castration-resistant prostate cancer (mCRPC) and optimize treatment.

Patient Population

Patients with prostate cancer who are eligible for treatment with 177Lutetium-prostate-specific membrane antigen-617 (177Lutetium-PSMA-617).

Intended Guideline Users

This guideline is targeted for clinicians involved in the care of patients with prostate cancer who are eligible for treatment with 177Lutetium-PSMA-617.

pdf download Full Report (PDF) (399.09 Ko)